Case Management of COVID-19 (Secondary Version)

Yasuyuki Kato

Abstract:
Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. Disease severity can be determined based on simple vital signs; some laboratory markers are useful adjuncts. Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials. For example, dexamethasone has now been considered as a standard therapy for severe cases, while remdesivir and tocilizumab are promising agents in selected patient groups.

Key Words:
COVID-19, disease severity, drug therapy, clinical trials, steroids

I. Introduction
Coronavirus disease 2019 (COVID-19) is defined as an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1)-(2). Its first case was reported in Wuhan, China, in December 2019 and, since then, has spread across the globe. As of March 7, 2021, about 116 million confirmed cases of COVID-19 have been recorded worldwide, including around 2.6 million deaths, as per the reports of the World Health Organization (WHO) (3). The clinical picture is broad, ranging from asymptomatic infection to upper respiratory tract infections, pneumonia, acute respiratory distress syndrome, and multiple organ failure (4). Majority of the fatal cases have been observed among older people or people who have underlying diseases (5).

Thus, case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world (6). Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials (7). Through these concerted efforts, dexamethasone has now been considered as a standard therapy for severe cases who require supplemental oxygen although many clinicians raised safety concerns for its use in the initial phase of the pandemic. In this paper, the clinical management of COVID-19 patients with mild to moderate disease is discussed focusing on Japanese clinical settings (8).

II. Management Based on Disease Severity
Patients suspected of having COVID-19 are required to undergo diagnostic testing for confirmation of the disease (polymerase chain reaction or antigen test). After confirming a diagnosis, it is also essential to screen the patients to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. During epidemics, it is vital to quickly and thoroughly take one’s medical history to obtain pertinent facts such as date of onset of symptoms, age and sex of the patient, and presence of any underlying disease.

Disease severity can be determined based on simple vital signs, including level of consciousness and respiratory rate as that of community-acquired pneumonia (7)-(9). However, some patients with COVID-19 do not complain of dyspnea despite the presence of respiratory failure (silent hypoxia); thus, it is desirable to measure percutaneous oxygen saturation (SpO₂) using a pulse oximeter (9). Patients with SpO₂ lower than 96% are suspected of having pneumonia and should thus be assessed further (9). Blood tests and imaging modalities add benefits to verify disease severity. Computed tomography (CT) is the method of choice for the early detection of pneumonia findings (ground-glass opacities) (10). Once the disease severity is identified based on SpO₂ and the patient’s clinical condi-
Table 1. Management of COVID-19 Patients Based on Disease Severity.

| Definitions | Place of medical care | Points of medical care |
|-------------|-----------------------|------------------------|
| Mild        | SpO₂ > 96             | Home                   | Persons should be observed from the day of onset up to 10 days. Symptoms may appear even in asymptomatic carriers. Regularly measure SpO₂ in the elderly or in those with underlying illness to detect early progression to moderate or more severe disease. Olfactory and taste disorders are likely to persist. |
|             | With no evidence of pneumonia | Medical institution (elderly, with underlying illness) |
| Moderate I  | 93 < SpO₂ < 96        | Medical institution    | Careful follow-up is required using respiratory rate and SpO₂ as indicators. In patients with decreased SpO₂, oxygen administration is started, and drug therapy (a combination of remdesivir and steroids) is recommended. Screening for thrombosis is also performed. Bacterial infections are rare, and the need for antibiotics is assessed on a case-by-case basis. |
| Moderate II | SpO₂ < 93             | Medical institution    |
| Severe      | Requires artificial ventilation | Advanced medical institution designated under the coordination of prefectures | It is desirable to receive treatment at an appropriate medical institution. |

COVID-19, coronavirus disease; SpO₂, percutaneous oxygen saturation

1. Antiviral drugs

Before the COVID-19 epidemic, no anti-coronavirus drugs have been developed; thus, attempts have been made, since the start of the pandemic, to repurpose existing antimicrobial or other potentially effective drugs for this condition. Clinical trials are currently being conducted on drugs that are effective against SARS-CoV-2 in vitro. However, as of March 2021, the number of drugs with established effects remains minimal. In Japan, remdesivir, which received urgent approval from the US Food and Drug Administration in May 2020, has been given special approval. Compassionate use of favipiravir, an anti-influenza drug stockpiled as a countermeasure against a novel strain of influenza virus, is being offered at the physician’s request. Some of the major drugs that are in clinical trials in Japan and overseas are also listed in Table 2.

i. Remdesivir

This is identified as a nucleic acid analog that was under development as an anti-Ebola virus drug. It acts by inhibiting viral RNA-dependent RNA polymerase. In several studies, a growth inhibitory effect on SARS-CoV-2 was shown. In an international joint clinical trial (double blind) led by the National Institutes of Health in the USA in patients with COVID-19 (moderate to severe), clinical symptoms improved faster in the group administered remdesivir than in the placebo group (10 days vs. 15 days). However, in an international joint clinical trial (single blind) led by the WHO, no reduction in case fatality rate was reported (Table 3). Thus, the effect of this drug is considered minimal in those with severe disease, but it is likely effective in patients with moderate disease. The standard dosage is as follows: for adults, 200 mg should be infused on the first day of adminis-
tration, while 100 mg should be administered daily from day 2 onward. The standard period of treatment is 5 days.

In Japan, remdesivir can be used in patients with moderate to severe pneumonia. Since the Ministry of Health, Labour and Welfare of Japan controls the supply of drugs, patient registration must be performed through a dedicated system when this drug is used.

ii. Favipiravir
This is an RNA-dependent RNA polymerase inhibitor. This drug has been licensed for pandemic influenza due to a novel strain and stockpiled as a part of pandemic preparedness in Japan. In vitro efficacy has also been shown for SARS-CoV-2, and an investigator-initiated clinical trial on mild cases and a sponsor-initiated clinical trial for NDA on moderate cases (both single blind) have been conducted so far in Japan. In the former, the number of days until a negative PCR test for SARS-CoV-2 was not different from that in the group not administered favipiravir. However, the treated group showed an early tendency of reduced fever though the difference was not statistically significant (18). Another open-label randomized clinical trial conducted in India demonstrated a shorter time to resolution of clinical signs and symptoms although it did not show a shorter time of virus shedding compared with the control group (19). Compassionate use of favipiravir has been permitted in Japan and other countries. There have been few adverse reactions reported in patients with COVID-19 treated by this drug. However, it is potentially teratogenic and is, thus, contraindicated in pregnant women.

iii. Other drugs
The HIV protease inhibitor, lopinavir/ritonavir, has been studied in small clinical trials against severe acute respiratory syndrome (SARS) and MERS (Middle East respiratory syn-

Figure 1. A clinical flowchart to select respiratory support modalities for COVID-19 cases. Ordinarily, SpO\textsubscript{2} \geq 93% should be maintained by a nasal cannula up to O\textsubscript{2} 5 L/min or an oxygen mask up to O\textsubscript{2} 10 L/min.

Note: When a nasal cannula is used, the patient should wear a surgical mask to suppress aerosol generation. Consider intubation if SpO\textsubscript{2} \geq 93% cannot be maintained even with O\textsubscript{2} administration by means of an oxygen mask. In addition, intubation or artificial respiration management should ideally be performed earlier than usual.

Note: Masks with a reservoir (10-15 L/min), nasal high-flow, and non-invasive positive pressure ventilation are normally considered at this stage, but there is a risk of nosocomial infection due to aerosol generation so the use of individual negatively pressurized rooms is desirable. Confirm that the flow is between 30 and 40 L/min when using high-flow and that the cannula is within the nasal cavity. In addition, have the patient wear a surgical mask to suppress aerosol generation.
drome) before the COVID-19 pandemic and showed potential efficacy. However, this drug did not reduce the case fatality recorded in patients with moderate to severe COVID-19 in well-designed clinical trials.\(^{(14)}\)\(^{(20)}\)

It was revealed that the antimalarial drug hydroxychloroquine is ineffective in reducing mortality and preventing the onset of the disease. Furthermore, well-designed clinical trials have failed to show its efficacy in treatment and post-exposure prophylaxis.\(^{(16)}\)\(^{(23)}\). Moreover, the WHO has not recommended this drug for COVID-19 in the recent guideline.

2. Immune modulator drugs

iv. Steroids

Steroids have been used in patients with MERS and SARS, but there have been concerns that they may delay virus clearance and increase case fatality rates. A well-designed clinical trial (RECOVERY) conducted in the UK demonstrated the efficacy of dexamethasone against severe COVID-19.\(^{(22)}\). A significant improvement in prognosis was seen in those requiring invasive mechanical ventilation. The case fatality rate within 28 days of enrolment was 29.0% in the treatment group as

Table 2. Drug Therapy for COVID-19.

| Developmental status | Drug name | Target patients |
|----------------------|-----------|-----------------|
| Interferon antiviral drug | Special approval | Remdesivir (RNA-dependent RNA polymerase inhibitor) | Moderate to severe cases requiring oxygen administration (less effective in severe cases) |
| Off-label use (compassionate use within the framework of observational studies) | Favipiravir (RNA-dependent RNA polymerase inhibitor) | Mild (although efficacy is uncertain) |
| Clinical trials | Lopinavir/ritonavir, nelfinavir (HIV protease inhibitor) | No efficacy in critically ill patients |
| Hydroxychloroquine (antimalarial drug) | No efficacy |
| Interferon | No efficacy |
| Ivermectin (anthelmintic drug) | Unclear efficacy |
| Ciclesonide (inhaled corticosteroid) | No efficacy |
| Immune modulator drugs | Approved | Dexamethasone (steroid) | Moderate to severe cases requiring oxygen administration |
| Clinical trials | Tocilizumab, sarilumab (genetically modified anti-IL-6 monoclonal antibody) | Unclear efficacy |
| Immunoglobinlin | Clinical trials | Recoveree’s plasma | Unclear efficacy |
| Antithrombotic drugs | Approved | Heparin | Moderate to severe cases requiring oxygen administration |

COVID-19, coronavirus disease; HIV, human immunodeficiency virus

Table 3. Remdesivir Clinical Trials.

| Trials | NCT04257656 | ACTT-1 | GS-US-540-5774 | SOLIDARITY |
|--------|-------------|--------|----------------|-----------|
| Implementing countries (number of facilities) | China (10) | United States (45), Denmark (8), United Kingdom (5), Greece (4), Germany (3), South Korea (2), Mexico (2), Spain (2), Japan (1), Singapore (1) | United States (45), Italy (11), Spain (9), United Kingdom (8), Germany (6), France (3), France (3), Switzerland (3), Singapore (3), Taiwan (3), Hong Kong (2), Netherlands (1) | World (unknown) |
| Implementation period | February-March 2020 | February-April 2020 | March-April 2020 | March-October 2020 |
| Study design | Double-blind | Double-blind | Unblind | Unblind |
| Number of cases | Remdesivir 158 Placebo 79 | Remdesivir 541 Placebo 521 | Remdesivir (5 days) 197 Remdesivir (10 days) 199 Standard treatment 200 | Remdesivir 2743 Standard treatment 2708 |
| Subjects | Requires hospitalization Pneumonia patients | Requires hospitalization Pneumonia patients | Requires hospitalization Patients with pneumonia (SpO\(_2\) > 94%) | Requires hospitalization Patients |
| Results | No significant difference in clinical improvement | Faster clinical improvement (10 days vs. 15 days) | On the 11th day of administration, the 5-day treatment group improved symptoms faster than the standard treatment group | No significant difference in mortality |

SpO\(_2\), percutaneous oxygen saturation
against 40.7% in the control group. Also, 21.5% of the dexamethasone-treated group who required oxygen administration at the time of enrolment died within 28 days after enrolment, compared with 25.0% of the control group. However, no prognostic improvement effect was observed in the group that did not require oxygen administration at the time of enrolment. Therefore, this drug is recommended to be administered as the standard therapy for patients with moderate to severe COVID-19 requiring oxygen therapy. The dose is 6 mg of dexamethasone once daily for 10 days. Other steroids probably have the same effect (hydrocortisone 160 mg once daily and methylprednisolone 16 mg every 12 hours)\(^{(23)}\).

**v. IL-6 inhibitors**

As significantly high serum CRP levels are noted in patients with severe COVID-19, the recombinant anti-IL-6 monoclonal antibodies, tocilizumab and sarilumab, have been expected to have immunomodulatory effects and improved prognosis\(^{(24)}\). As of March 2021, at least five clinical trial results have been published as peer-reviewed articles. A clinical trial on critically ill patients in the ICU conducted in the USA showed that tocilizumab (8 mg per kilogram of body weight) and sarilumab (400 mg) produced shorter organ support-free days and improved survival\(^{(25)}\). However, another clinical trial on severe cases conducted in the USA revealed no efficacy\(^{(26)}\).

### 3. Globulin preparation

Clinical trials are being conducted under the hypothesis that the anti-SARS-CoV-2 antibody in the plasma of recovered patients will suppress viral growth and have immunomodulatory effects in patients with the disease. The limited number of studies has been published as of March 2021. One clinical trial conducted in the USA showed that early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults has reduced the progression of COVID-19\(^{(27)}\). An observational study which included over 3,000 patients with COVID-19 in the USA supported the survival benefit of high-titer convalescent plasma\(^{(28)}\).

### 4. Antithrombotic drug

Pulmonary thromboembolism can cause respiratory failure and, ultimately, death in patients with COVID-19, with frequent coagulation abnormalities seen in those with moderate and severe diseases requiring oxygen administration\(^{(29)}\). High D-dimer levels are identified as a vital marker of suspected thrombosis. In these patients, anticoagulant therapy, such as heparin, is administered. Low-molecular heparin has not been approved for this indication in Japan.

**IV. Post-acute Care**

Hospitalization recommendations and work restrictions to prevent the spread of the disease will be lifted 10 days after the onset and 3 days after the symptoms improvement\(^{(7)}\). Most recovered patients do not require any further treatment. However, if symptoms are prolonged, such as fatigue, dysosmia, and dysgeusia, the patient should be monitored closely in an outpatient setting\(^{(30)}\). These clinical manifestations called post-COVID syndrome or long COVID are emerging issues and should thus be further examined under a prospective cohort study.

**V. Conclusion**

It seems that many patients infected with COVID-19 could not receive appropriate medical care because of limited bed availability in hospitals in most countries. Thus, creating a system to observe mildly ill patients, who may suffer from severe disease at later stages, at home or in designated accommodations in the community is a topic that requires consideration. To reduce the case fatality rate, it is vital to ensure standard treatment at an appropriate time. The coordination of healthcare resources in the community is key to reduce overall mortality.

Treatment for COVID-19 is largely supportive, but it is worth noting that many clinical trials have been conducted globally during the pandemic, and some medications have been proven to be effective against COVID-19. There is hope for more effective therapeutics available in the near future.

**Article Information**

**Conflicts of Interest**

Yasuyuki Kato received consultant fee from Fujifilm Toyama Pharmaceutical, Co.

**Sources of Funding**

This work was supported by Health Labour Sciences Research Grant (2020HA20).

**Acknowledgement**

I appreciate the board members of JAPAN COVID-19 Case Management Guide Review Committee for their contribution to this work.

The original version is available at https://www.med.or.jp/cme/jjma/newmag/15002/15002.html. The Editors-in-Chief of the Journal of the Japan Medical Association and JMA Journal have permitted the publication of this manuscript.

This is the secondary version of the previous article\(^{(31)}\) published in Japanese on 1 May 2021.

**References**

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med.
2. Coronavirus Study Group of the International Committee on Taxonomy of Viruses, Gorbalsen A E, Baker SC, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-44.

3. World Health Organization. COVID-19 Weekly epidemiological update-9 March 2021. [Internet]. [cited 2021 Mar 12]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---9-march-2021.

4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.

5. Zhou F, Yu Y, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.

6. Rosenbaum L. Facing Covid-19 in Italy-ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med. 2020;382:1873-5.

7. World Health Organization. COVID-19 clinical management: living guidance; January 25, 2021. [Internet]. [cited 2021 Mar 12]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.

8. JAPAN COVID-19 Case Management Guide Review Committee. Clinical management of patients with COVID-19: a guide for front-line healthcare workers. Version 2.1. [Internet]. [cited 2021 Mar 12]. Available from: https://www.mhlw.go.jp/content/000646531.pdf.

9. Wilkerson RG, Adler JD, Shan NG, et al. Silent hypoxia: a harbinger of clinical deterioration in patients with COVID-19. Am J Emerg Med. 2020;38(10):2243.e5-6.

10. Shi H, Han X, Jiang N. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-34.

11. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370.

12. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;17:1061-9.

13. World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed. Interim guidance. [Internet]. [cited 2021 Mar 12]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2020.4.

14. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 Interim WHO Solidarity trial results. N Engl J Med. 2021;384(6):497-511.

15. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—Final report. N Engl J Med. 2020;382(19):1813-26.

16. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048-57.

17. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.

18. Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64(12):e01897-20.

19. Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62-71.

20. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-99.

21. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517-25.

22. The RECOVERY Collaborative Group; Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19—Preliminary report. N Engl J Med. 2021;384(8):693-704.

23. World Health Organization. Corticosteroids for COVID-19: Living guidance; September 2, 2020. [Internet]. [cited 2021 Mar 12]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.

24. Algharbi SK, Acunsa VS. Supportive treatment with tocilizumab for Covid-19: a systematic review. J Clin Virol. 2020;127:104380.

25. The REMAP - CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

26. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(8):693-704.

27. Libster R, Marc GP, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610-8.

28. Joyner MJ, Carter RE, Seneffeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(8):693-704.

29. Liu Y, Cai J, Wang C, et al. Incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2021; Ahead of print.

30. Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID Syndrome (PPCS). Clin Rev Allergy
31. Kato Y. Case management of COVID-19. J Jpn Med Assoc. 2021;251-5, Japanese.